These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 22992943)

  • 1. Likeability and abuse liability of commonly prescribed opioids.
    Wightman R; Perrone J; Portelli I; Nelson L
    J Med Toxicol; 2012 Dec; 8(4):335-40. PubMed ID: 22992943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous oxycodone, hydrocodone, and morphine in recreational opioid users: abuse potential and relative potencies.
    Stoops WW; Hatton KW; Lofwall MR; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2010 Oct; 212(2):193-203. PubMed ID: 20665209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers.
    Walsh SL; Nuzzo PA; Lofwall MR; Holtman JR
    Drug Alcohol Depend; 2008 Dec; 98(3):191-202. PubMed ID: 18606504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxycodone in the Opioid Epidemic: High 'Liking', 'Wanting', and Abuse Liability.
    Kibaly C; Alderete JA; Liu SH; Nasef HS; Law PY; Evans CJ; Cahill CM
    Cell Mol Neurobiol; 2021 Jul; 41(5):899-926. PubMed ID: 33245509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Within-subject comparison of the psychopharmacological profiles of oral oxycodone and oral morphine in non-drug-abusing volunteers.
    Zacny JP; Lichtor SA
    Psychopharmacology (Berl); 2008 Jan; 196(1):105-16. PubMed ID: 17899018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
    Cicero TJ; Inciardi JA; Muñoz A
    J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender difference in prescription opioid abuse: A focus on oxycodone and hydrocodone.
    Graziani M; Nisticò R
    Pharmacol Res; 2016 Jun; 108():31-38. PubMed ID: 27107788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.
    Tompkins DA; Lanier RK; Harrison JA; Strain EC; Bigelow GE
    Psychopharmacology (Berl); 2010 Jul; 210(4):471-80. PubMed ID: 20386884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Within-subject comparison of the psychopharmacological profiles of oral hydrocodone and oxycodone combination products in non-drug-abusing volunteers.
    Zacny JP; Gutierrez S
    Drug Alcohol Depend; 2009 Apr; 101(1-2):107-14. PubMed ID: 19118954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products.
    Zacny JP; Gutierrez S
    Pain Med; 2008; 9(4):433-43. PubMed ID: 18489634
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abuse liability assessment of hydrocodone under current draft regulatory guidelines.
    Gauvin DV; McComb M; Code R; Dalton JA; Baird TJ
    J Pharmacol Toxicol Methods; 2015; 75():118-29. PubMed ID: 25969422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
    Vosburg SK; Severtson SG; Dart RC; Cicero TJ; Kurtz SP; Parrino MW; Green JL
    J Pain; 2018 Apr; 19(4):439-453. PubMed ID: 29224919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011.
    Atluri S; Sudarshan G; Manchikanti L
    Pain Physician; 2014; 17(2):E119-28. PubMed ID: 24658483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
    Cicero TJ; Surratt H; Inciardi JA; Munoz A
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.
    Cassidy TA; Oyedele N; Mickle TC; Guenther S; Budman SH
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1071-1082. PubMed ID: 28771942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major increases in opioid analgesic abuse in the United States: concerns and strategies.
    Compton WM; Volkow ND
    Drug Alcohol Depend; 2006 Feb; 81(2):103-7. PubMed ID: 16023304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder.
    Cassidy TA; Thorley E; Black RA; DeVeaugh-Geiss A; Butler SF; Coplan P
    J Opioid Manag; 2017; 13(6):425-440. PubMed ID: 29308589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient characteristics and risks factors for development of dependence on hydrocodone and oxycodone.
    Miller NS; Greenfeld A
    Am J Ther; 2004; 11(1):26-32. PubMed ID: 14704593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the subjective, psychomotor, and physiological effects of a hydrocodone/acetaminophen product in recreational drug users.
    Zacny JP; Gutierrez S; Bolbolan SA
    Drug Alcohol Depend; 2005 Jun; 78(3):243-52. PubMed ID: 15893155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New depression diagnosis following prescription of codeine, hydrocodone or oxycodone.
    Scherrer JF; Salas J; Bucholz KK; Schneider FD; Burroughs T; Copeland LA; Sullivan MD; Lustman PJ
    Pharmacoepidemiol Drug Saf; 2016 May; 25(5):560-8. PubMed ID: 27004714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.